| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | nelarabine | CTRPv2 | pan-cancer | AAC | 0.45 | 3e-24 |
| mRNA | Cytarabine | CTRPv2 | pan-cancer | AAC | 0.29 | 2e-18 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.3 | 6e-16 |
| mRNA | GSK461364 | CTRPv2 | pan-cancer | AAC | 0.29 | 6e-15 |
| mRNA | carboplatin:etoposide (40:17 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.27 | 2e-14 |
| mRNA | alisertib | CTRPv2 | pan-cancer | AAC | 0.28 | 1e-13 |
| mRNA | decitabine | CTRPv2 | pan-cancer | AAC | 0.24 | 3e-13 |
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | 0.27 | 8e-13 |
| mRNA | etoposide | CTRPv2 | pan-cancer | AAC | 0.25 | 1e-12 |
| mRNA | STF-31 | CTRPv2 | pan-cancer | AAC | 0.29 | 2e-12 |